Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
Tempus AI, Inc. (NASDAQ: TEM) announces an expanded collaboration with Takeda to enhance oncology research and development. The partnership leverages Tempus' de-identified multimodal datasets and biological modeling capabilities to advance Takeda's cancer therapeutics pipeline. Takeda researchers will use Tempus' analytics platform, Lens, to access de-identified patient records and AI-enabled tools.
The collaboration includes a multi-phase biological modeling project using one of the world's largest repositories of patient-derived tumor organoids. Tempus is working with Takeda on a panel of 60 organoids spanning 10 cancer indications to evaluate preclinical candidates. This approach aims to enhance drug effectiveness prediction and guide early candidate prioritization.
Initial work has already yielded research to be presented at an upcoming medical congress, demonstrating the potential of this data-first approach in accelerating insights for drug development.
Tempus AI, Inc. (NASDAQ: TEM) annuncia una collaborazione ampliata con Takeda per migliorare la ricerca e lo sviluppo in oncologia. Il partenariato sfrutta i dataset multimodali de-identificati di Tempus e le capacità di modellazione biologica per avanzare la pipeline dei terapeutici oncologici di Takeda. I ricercatori di Takeda utilizzeranno la piattaforma analitica Lens di Tempus per accedere ai registri paziente de-identificati e agli strumenti abilitati dall'IA.
La collaborazione include un progetto di modellazione biologica in multi-fase che utilizza uno dei più grandi repository al mondo di organoidi tumorali derivati dai pazienti. Tempus sta lavorando con Takeda su un pannello di 60 organoidi che coprono 10 indicazioni oncologiche per valutare i candidati preclinici. Questo approccio mira a migliorare la previsione dell'efficacia del farmaco e a orientare la priorizzazione dei candidati precoci.
I lavori iniziali hanno già portato a ricerche che saranno presentate in un prossimo congresso medico, dimostrando il potenziale di questo approccio basato sui dati nell'accelerare le intuizioni per lo sviluppo dei farmaci.
Tempus AI, Inc. (NASDAQ: TEM) anuncia una colaboración ampliada con Takeda para mejorar la investigación y desarrollo en oncología. La asociación aprovecha los conjuntos de datos multimodales desidentificados de Tempus y las capacidades de modelado biológico para avanzar en la cartera de terapias oncológicas de Takeda. Los investigadores de Takeda utilizarán la plataforma analítica Lens de Tempus para acceder a registros de pacientes desidentificados y herramientas habilitadas por IA.
La colaboración incluye un proyecto de modelado biológico en múltiples fases utilizando uno de los mayores repositorios del mundo de organoides tumorales derivados de pacientes. Tempus está trabajando con Takeda en un panel de 60 organoides que abordan 10 indicaciones de cáncer para evaluar candidatos preclínicos. Este enfoque tiene como objetivo mejorar la predicción de efectividad de los fármacos y guiar la priorización temprana de candidatos.
El trabajo inicial ya ha producido investigaciones que se presentarán en un próximo congreso médico, demostrando el potencial de este enfoque centrado en los datos para acelerar los conocimientos en el desarrollo de medicamentos.
템퍼스 AI, Inc. (NASDAQ: TEM)는 타케다와의 협력을 확대하여 종양학 연구 및 개발을 강화한다고 발표했습니다. 이 파트너십은 템퍼스의 비식별 다중 모드 데이터 세트와 생물학적 모델링 역량을 활용하여 타케다의 암 치료제 파이프라인을 발전시킵니다. 타케다 연구자들은 템퍼스의 분석 플랫폼인 Lens를 사용하여 비식별 환자 기록 및 AI 지원 도구에 접근할 것입니다.
이 협력은 세계 최대의 환자 유래 종양 오르가노이드 저장소 중 하나를 사용한 다단계 생물학적 모델링 프로젝트를 포함합니다. 템퍼스는 타케다와 협력하여 10개의 암 적응증에 걸쳐 60개의 오르가노이드 패널을 평가하여 전임상 후보를 평가합니다. 이 접근법은 약물 효과 예측을 향상시키고 초기 후보 우선 순위를 안내하는 것을 목표로 합니다.
초기 연구는 이미 곧 있을 의료 학회에서 발표될 연구 결과를 도출했으며, 데이터 우선 접근법이 약물 개발 통찰력을 가속하는 데 잠재력을 가지고 있음을 보여줍니다.
Tempus AI, Inc. (NASDAQ: TEM) annonce une collaboration élargie avec Takeda pour améliorer la recherche et le développement en oncologie. Le partenariat tire parti des ensembles de données multimodales dé-identifiés de Tempus et des capacités de modélisation biologique pour faire avancer le pipeline de traitements anticancéreux de Takeda. Les chercheurs de Takeda utiliseront la plateforme d’analyse Lens de Tempus pour accéder aux dossiers de patients dé-identifiés et aux outils alimentés par l'IA.
La collaboration comprend un projet de modélisation biologique en plusieurs phases utilisant l'une des plus grandes réserves au monde d'organoïdes tumoraux dérivés de patients. Tempus travaille avec Takeda sur un panel de 60 organoïdes couvrant 10 indications de cancer pour évaluer les candidats précliniques. Cette approche vise à améliorer la prédiction de l’efficacité des médicaments et à orienter la priorisation des premiers candidats.
Les travaux initiaux ont déjà produit des recherches qui seront présentées lors d’un prochain congrès médical, démontrant le potentiel de cette approche axée sur les données pour accélérer les connaissances sur le développement de médicaments.
Tempus AI, Inc. (NASDAQ: TEM) kündigt eine erweiterte Zusammenarbeit mit Takeda an, um die Forschung und Entwicklung in der Onkologie zu verbessern. Die Partnerschaft nutzt die de-identifizierten multimodalen Datensätze von Tempus und die biologischen Modellierungsfähigkeiten, um die Pipeline der Krebsmedikamente von Takeda voranzutreiben. Die Forscher von Takeda werden die Analyseplattform Lens von Tempus nutzen, um auf de-identifizierte Patientenakten und KI-unterstützte Werkzeuge zuzugreifen.
Die Zusammenarbeit umfasst ein mehrphasiges biologisches Modellierungsprojekt, das auf einem der weltweit größten Archive von patientenabgeleiteten Tumororganoiden basiert. Tempus arbeitet mit Takeda an einem Panel von 60 Organoiden, die 10 Krebsindikationen abdecken, um präklinische Kandidaten zu bewerten. Dieser Ansatz zielt darauf ab, die Vorhersage der Wirksamkeit von Arzneimitteln zu verbessern und die frühzeitige Priorisierung von Kandidaten zu leiten.
Erste Arbeiten haben bereits zu Forschungsarbeiten geführt, die auf einem kommenden medizinischen Kongress präsentiert werden, und zeigen das Potenzial dieses datengestützten Ansatzes, um Erkenntnisse zur Arzneimittelentwicklung zu beschleunigen.
- Expansion of collaboration with major pharmaceutical company Takeda
- Access to Tempus' large multimodal datasets and biological modeling capabilities
- Potential acceleration of Takeda's oncology drug development pipeline
- Use of advanced AI-enabled analytics platform (Lens) for real-time data access
- Utilization of one of the world's largest patient-derived tumor organoid repositories
- None.
Insights
This expanded collaboration between Tempus and Takeda represents a significant advancement in data-driven oncology research. By leveraging Tempus' AI-powered analytics platform and extensive multimodal datasets, Takeda gains a powerful tool for accelerating drug development across various modalities, including ADCs, small molecules, bispecifics and gamma delta T-cell therapies.
The integration of Tempus' patient-derived tumor organoids with real-world data is particularly noteworthy. This approach could dramatically enhance the predictive power of preclinical studies, potentially reducing the time and cost of bringing new oncology treatments to market. The focus on a panel of 60 organoids across 10 cancer indications suggests a broad and ambitious scope for this collaboration.
For investors, this partnership underscores Tempus' growing influence in the precision medicine space and its ability to attract major pharmaceutical partners. The potential for accelerated drug development and more targeted therapies could lead to significant long-term value creation for both companies.
The expansion of this collaboration marks a significant step forward in translational oncology research. By combining Tempus' real-world data with biological modeling, Takeda is positioning itself at the forefront of precision oncology drug development. The use of patient-derived organoids linked to comprehensive genomic and clinical data is a powerful approach that could significantly improve the predictive value of preclinical studies.
The mention of upcoming research presentations suggests that this collaboration is already yielding actionable insights. The focus on a diverse range of therapeutic modalities, including cutting-edge approaches like gamma delta T-cell therapies, indicates that Takeda is pursuing a multifaceted strategy in oncology.
This data-driven approach has the potential to not only accelerate drug development but also to enhance the precision of patient selection for clinical trials, potentially leading to higher success rates and more efficient use of resources in the challenging field of oncology drug development.
After an initial collaboration that leveraged Tempus’ de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus’ multimodal real-world datasets and Tempus’ biological modeling capabilities to advance Takeda’s pipeline of cancer therapeutics, which includes antibody-drug conjugates (ADCs), small molecules, bispecifics and gamma delta T-cell therapies.
Takeda researchers will use Tempus’ analytics platform, Lens, to gain real-time access to de-identified patient records as well as a suite of AI-enabled tools to accelerate critical insights for Takeda’s drug development efforts. Initial work has resulted in research that will be presented at an upcoming medical congress.
In parallel, the two companies have embarked on a multi-phase biological modeling project leveraging one of the largest repositories of patient-derived tumor organoids in the world. Each organoid model can be used to reflect the biology of a distinct patient tumor, and then be genetically linked through Tempus’ next-generation sequencing assays to Tempus’ real-world multimodal dataset, potentially enhancing the predictability of a drug’s effectiveness. This approach enables efficient hypothesis generation and rapid validation that could guide early drug candidate prioritization. For this unique scope of work, Tempus is working with Takeda on a panel of 60 organoids spanning 10 cancer indications that closely reflect real-world patients to functionally evaluate several preclinical candidates.
“We are excited to expand our relationship with Takeda, combining real-world multimodal data and biological modeling capabilities to better understand targets of interest,” said Ryan Fukushima, Chief Operating Officer at Tempus. “The results we’ve seen thus far demonstrate how the collaboration between the Takeda and Tempus teams can assist in efforts to accelerate Takeda’s growing oncology therapeutic pipeline, which may lead to the next generation of cancer treatments.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of the collaboration with Takeda to use data and biological modeling to advance therapeutic research and discovery. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240926598796/en/
Erin Carron
erin.carron@tempus.com
Source: Tempus AI, Inc.
FAQ
What is the purpose of Tempus' expanded collaboration with Takeda?
How will Takeda use Tempus' analytics platform in the collaboration?
What is the scope of the biological modeling project between Tempus (TEM) and Takeda?
How might this collaboration impact Tempus' (TEM) stock performance?
